We are at the origin of an innovation in the field of biomarkers with the demonstration of a relationship between the cancerous monitoring of a living being and the isotopic variation of copper (dCu). Our large database of data obtained on more than 6000 human or animal samples allows us to have a good knowledge of the natural and pathological variations of this biomarker. Our technology is also used in the field of neurodegenerative diseases or with doctors specializing in anti-aging medicine.
Our core business is the use of this cancer marker in the veterinary field and especially pets (especially dogs) but also zoo girls because we now have a good database on this type of animals.
Our first clinical follow-up studies of over 100 dogs show very good results and are much more specific than the commonly used data such as CRP or other inflamation markers.
Indeed, after a follow-up of two years on 77 dogs, we can say that our biomarker allows the diagnosis of > 85% of cancers (lymphoma) and this can go up to 99% if we add the measure of TK1. In addition, we were able to obtain more than 85% (copper alone) cancer recurrence detection over the two-years period of dog tracking. No other biomarker or biomarker combination achieves this level of performance.
